JP2018155752A - がんを診断および処置する方法 - Google Patents

がんを診断および処置する方法 Download PDF

Info

Publication number
JP2018155752A
JP2018155752A JP2018046822A JP2018046822A JP2018155752A JP 2018155752 A JP2018155752 A JP 2018155752A JP 2018046822 A JP2018046822 A JP 2018046822A JP 2018046822 A JP2018046822 A JP 2018046822A JP 2018155752 A JP2018155752 A JP 2018155752A
Authority
JP
Japan
Prior art keywords
cancer
subject
sample
blood sample
ctc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018046822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018155752A5 (enExample
Inventor
ツェン・ジュー−ユー
Ju-Yu Tseng
チェン・イェン−ルー
Yen-Ru Chen
リー・チア−イン
Chia-Ying Lee
ウー・リィ−ファン
Li-Fan Wu
ワン・シン−ハン
Shin-Hang Wang
チェン・ジュイ−リン
Jui-Lin Chen
チェン・チュウェン−チョン
Chwen-Cheng Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Micareo Taiwan Co Ltd
Original Assignee
Micareo Taiwan Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Micareo Taiwan Co Ltd filed Critical Micareo Taiwan Co Ltd
Publication of JP2018155752A publication Critical patent/JP2018155752A/ja
Publication of JP2018155752A5 publication Critical patent/JP2018155752A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/492—Determining multiple analytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • Physiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2018046822A 2017-03-14 2018-03-14 がんを診断および処置する方法 Pending JP2018155752A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762471083P 2017-03-14 2017-03-14
US62/471,083 2017-03-14
US201762584634P 2017-11-10 2017-11-10
US62/584,634 2017-11-10

Publications (2)

Publication Number Publication Date
JP2018155752A true JP2018155752A (ja) 2018-10-04
JP2018155752A5 JP2018155752A5 (enExample) 2021-04-30

Family

ID=61868129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018046822A Pending JP2018155752A (ja) 2017-03-14 2018-03-14 がんを診断および処置する方法

Country Status (8)

Country Link
US (1) US20180267046A1 (enExample)
EP (1) EP3376227B1 (enExample)
JP (1) JP2018155752A (enExample)
KR (1) KR20180105091A (enExample)
CN (1) CN108572255B (enExample)
AU (1) AU2018201819A1 (enExample)
CA (1) CA2998065A1 (enExample)
TW (1) TWI786095B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110142068B (zh) * 2019-06-12 2024-02-02 杭州华得森生物技术有限公司 一种上皮间质混合型循环肿瘤细胞检测试剂盒及方法
CN111562375B (zh) * 2020-04-20 2022-05-06 山东第一医科大学(山东省医学科学院) 一种检测胃癌患者外周血循环肿瘤细胞pd-l1表达的免疫荧光试剂盒及检测方法
CN111551718A (zh) * 2020-04-20 2020-08-18 山东第一医科大学(山东省医学科学院) 一种检测前列腺癌患者外周血循环肿瘤细胞pd-l1表达的免疫荧光试剂盒及检测方法
TWI874453B (zh) * 2020-09-17 2025-03-01 日商細胞雲股份有限公司 使用末稍血循環腫瘤細胞之解析的癌症治療方法
RU2738563C1 (ru) * 2020-09-18 2020-12-14 Ен Джун Чой Способ прогноза малигнизации и ранней диагностики злокачественных опухолей

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096734A2 (en) * 2009-02-20 2010-08-26 John Wayne Cancer Institute B7-h3 antibody coupled bead assay for isolation and detection of circulating tumor cells in body fluids of melanoma and breast cancer patients
WO2016061064A1 (en) * 2014-10-15 2016-04-21 Epic Sciences, Inc. Circulating tumor cell diagnostics for therapy targeting pd-l1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010096734A2 (en) * 2009-02-20 2010-08-26 John Wayne Cancer Institute B7-h3 antibody coupled bead assay for isolation and detection of circulating tumor cells in body fluids of melanoma and breast cancer patients
WO2016061064A1 (en) * 2014-10-15 2016-04-21 Epic Sciences, Inc. Circulating tumor cell diagnostics for therapy targeting pd-l1

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ARUN SATELLI: "Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells", SCIENTIFIC REPORTS, vol. 6, JPN6022005350, 1 July 2016 (2016-07-01), pages 28910, ISSN: 0004876357 *
ARUTHA KULASINGHE: "PD-L1 expressing circulating tumour cells in head and neck cancers", BMC CANCER, vol. 17, JPN6022005357, 16 May 2017 (2017-05-16), pages 333, ISSN: 0004705605 *
CHIARA NICOLAZZO: "Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated wit", SCIENTIFIC REPORTS, vol. 6, JPN6022005362, 24 August 2016 (2016-08-24), pages 31726, ISSN: 0004705609 *
E. SAADA-BOUZID: "Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head an", ANNALS OF ONCOLOGY, vol. 28, JPN6022005366, 13 April 2017 (2017-04-13), pages 1605 - 1611, ISSN: 0004705612 *
ERIC DENEVE: "Capture of Viable Circulating Tumor Cells in the Liver of Colorectal Cancer Patients", CLINICAL CHEMISTRY, vol. 59, no. 9, JPN6022005355, 2013, pages 1384 - 1392, ISSN: 0004705604 *
KOUTSODONTIS, GEORGE: "pdl1-expressing circulating tumor cells (ctcs) in head and neck squamous cell carcinoma (hnscc).", JOURNAL OF CLINICAL ONCOLOGY, vol. Vol.33 No.15 Suppl, JPN6022005349, 2015, pages 6018, ISSN: 0004876356 *
KYLE P. MCMULLEN: "Circulating tumor cells in head and neck cancer: A review", WORLD JOURNAL OF OTORHINOLARYNGOLOGY-HEAD AND NECK SURGERY, vol. 2, JPN6022005364, 21 July 2016 (2016-07-21), pages 109 - 116, ISSN: 0004705611 *
R.L. FERRIS: "Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck", N ENGL J MED, vol. 375, JPN6022005360, 9 October 2016 (2016-10-09), pages 1856 - 1867, ISSN: 0004705607 *
SALVATORE GRISANTI: "Circulating Tumor Cells in Patients with Recurrent or Metastatic Head and Neck Carcinoma: Prognostic", PLOS ONE, vol. 9, no. 8, JPN6022005353, 8 August 2014 (2014-08-08), pages 103918, ISSN: 0004876358 *
SCOTT E. STROME: "B7-H1 Blockade Augments Adoptive T-Cell Immunotherapy for Squamous Cell Carcinoma", CANCER RESEARCH, vol. 63, JPN6022005363, 1 October 2003 (2003-10-01), pages 6501 - 6505, ISSN: 0004705610 *
XIN WANG: "PD-L1 expression in human cancers and its association with clinical outcomes", ONCOTARGETS AND THERAPY, vol. 9, JPN6022005361, 2016, pages 5023 - 5039, ISSN: 0004705608 *
YUEH-MIN LIN: "High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in Oral Squamous Cell Carcinoma", PLOS ONE, vol. 10, no. 11, JPN6022005359, 12 November 2015 (2015-11-12), pages 0142656, ISSN: 0004705606 *

Also Published As

Publication number Publication date
EP3376227A1 (en) 2018-09-19
AU2018201819A1 (en) 2018-10-04
US20180267046A1 (en) 2018-09-20
KR20180105091A (ko) 2018-09-27
CA2998065A1 (en) 2018-09-14
CN108572255B (zh) 2023-05-16
CN108572255A (zh) 2018-09-25
TWI786095B (zh) 2022-12-11
EP3376227B1 (en) 2024-02-21
TW201902534A (zh) 2019-01-16
EP3376227C0 (en) 2024-02-21

Similar Documents

Publication Publication Date Title
Catenacci et al. Acquisition of portal venous circulating tumor cells from patients with pancreaticobiliary cancers by endoscopic ultrasound
Li et al. Clinical significance of circulating tumor cells and tumor markers in the diagnosis of lung cancer
Cauley et al. Circulating epithelial cells in patients with pancreatic lesions: clinical and pathologic findings
Jin et al. Evaluation of the diagnostic value of circulating tumor cells with CytoSorter® CTC capture system in patients with breast cancer
Abdallah et al. Thymidylate synthase expression in circulating tumor cells: A new tool to predict 5‐fluorouracil resistance in metastatic colorectal cancer patients
JP2018155752A (ja) がんを診断および処置する方法
JP6485759B2 (ja) 末梢循環腫瘍細胞単位の悪性度の検出方法及びそのキット
Liu et al. Circulating tumor cells as a biomarker in pancreatic ductal adenocarcinoma
Cheng et al. Enumeration and characterization of circulating tumor cells and its application in advanced gastric cancer
van der Toom et al. Analogous detection of circulating tumor cells using the AccuCyte®—CyteFinder® system and ISET system in patients with locally advanced and metastatic prostate cancer
Chang et al. PD-L1 expression in Xp11. 2 translocation renal cell carcinoma: indicator of tumor aggressiveness
Kaifi et al. L1 (CD171) is highly expressed in gastrointestinal stromal tumors
Kim et al. Detection of circulating tumor cells and their potential use as a biomarker for advanced renal cell carcinoma
Levy et al. Analysis of cell-free DNA to assess risk of tumoremia following endoscopic ultrasound fine-needle aspiration of pancreatic adenocarcinomas
Shen et al. Correlation between human leukocyte antigen-G expression and clinical parameters in oral squamous cell carcinoma
Frăţilă et al. COX-2 and Ki-67 immunohistochemical markers in the assessment of long-standing ulcerative colitis associated dysplasia
Vassalou et al. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy
Tkaczuk et al. The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method
Zhao et al. Use of the Malaria Protein VAR2CSA for the Detection of Small Extracellular Vesicles to Diagnose Adenocarcinoma
Gafeer et al. Diagnostic utility of PD-L1 expression in lung adenocarcinoma: immunohistochemistry and RNA in situ hybridization
Zhang et al. Combined detection of SHOX2 and PTGER4 methylation with serum marker CYFRA21-1 for improved diagnosis of malignant pleural mesothelioma
EP3215851B1 (en) Lung cancer sub-typing method
EP3676295B1 (en) Phenotypic profiling of hepatocellular carcinoma circulating tumor cells for treatment selection
Zhou et al. HBXIP protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas
Zhou et al. Circulating endothelial cells and their subsets: novel biomarkers for cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210312

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220215

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220920